Drug Profile
Nirsevimab - Astrazeneca
Alternative Names: Anti-RSV-4-monoclonal antibody - AstraZeneca; Anti-RSV-mAb-D25; Anti-RSV-MAb-YTE; Anti-RSV-monoclonal antibody - AstraZeneca; BEYFORTUS; Beyfortus; D25; MEDI 8897; nirsevimab-alip; Respiratory-syncytial-virus-monoclonal-antibody-D25; SP 0232Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator AIMM Therapeutics
- Developer AstraZeneca; Sanofi
- Class Antivirals; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Respiratory syncytial virus infections
Most Recent Events
- 27 Mar 2024 Registered for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Japan (IM)
- 27 Mar 2024 Nirsevimab receives Priority Review Designation for Respiratory syncytial virus infections in China prior to March 2024
- 27 Mar 2024 Adverse events and efficacy data from the phase-II/III MEDLEY trial in Respiratory syncytial virus infections released by AstraZeneca